
SFA Therapeutics
SFA Therapeutics: Developing oral drugs to treat cancer and autoimmune diseases by regulating the immune system.

SFA Therapeutics: Developing oral drugs to treat cancer and autoimmune diseases by regulating the immune system.
SFA Therapeutics was founded with the mission to develop therapeutically-tailored oral drugs that regulate the immune system using bacterial metabolites. The company focuses on treating autoimmune diseases and cancers originating from chronic inflammation. Their innovative approach aims to block the root causes of these conditions with safe, orally administered drugs. SFA Therapeutics targets a significant market, addressing the needs of over 100 million patients suffering from autoimmune diseases.
Notable figures affiliated with SFA Therapeutics include experts in immunology and pharmacology, though specific names are not provided. The company has made significant strides in drug development, particularly in creating treatments for psoriasis, liver cancer, and other chronic inflammatory diseases. Their platform promises faster clinical development and safer treatments due to the use of endogenous biosynthetics. SFA Therapeutics is poised to make a substantial impact on the healthcare industry by offering novel solutions for chronic inflammatory conditions.
Companies similar to SFA Therapeutics include Forward Therapeutics, Lapix Therapeutics, Rise Therapeutics and Invea Therapeutics.
SFA Therapeutics was founded in 2016.
SFA Therapeutics' headquarters is located in Jenkintown, PA, US.
SFA Therapeutics' most recent funding round was for $4.5M (USD) in November 2023.
As of Nov 9, 2023, SFA Therapeutics has disclosed funding of $8.7M (USD). Undisclosed round amounts are excluded.
SFA Therapeutics has 6 employees as of Feb 4, 2024.

Invea Therapeutics
inveatx.com